Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-64531 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-p300 (Ser1834) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Phospho-p300 (Ser1834) Polyclonal Antibody detects endogenous levels of p300 only when phosphorylated at Ser1834.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references P300-dependent acetylation of histone H3 is required for epidermal growth factor receptor-mediated high-mobility group protein A2 transcription in hepatocellular carcinoma.
Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis.
Liang C, Niu J, Wang X, Zhang ZS, Yang RH, Yao X, Liu FY, Li WQ, Pei SH, Sun H, Wang CJ, Fang D, Xie SQ
Cancer science 2021 Feb;112(2):679-690
Cancer science 2021 Feb;112(2):679-690
Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis.
Rubio K, Singh I, Dobersch S, Sarvari P, Günther S, Cordero J, Mehta A, Wujak L, Cabrera-Fuentes H, Chao CM, Braubach P, Bellusci S, Seeger W, Günther A, Preissner KT, Wygrecka M, Savai R, Papy-Garcia D, Dobreva G, Heikenwalder M, Savai-Pullamsetti S, Braun T, Barreto G
Nature communications 2019 May 20;10(1):2229
Nature communications 2019 May 20;10(1):2229
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of p300 in PMA treated HeLa whole cell lysates using a Phospho-p300 (Ser1834) Polyclonal Antibody (Product # PA5-64531).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- 3 Figure Akt-dependent p300 phosphorylation mediates epidermal growth factor (EGF)-induced increase in high-mobility group protein A2 (HMGA2) transcription in SNU-368 cells. Western blot analysis suggests that EGF induced an increase in the level of Akt Ser473 (A) and p300 Ser1834 (B) phosphorylation in SNU-368 cells. *P < .05, **P < .01, ***P < .001, one-way ANOVA, n = 6 per group. C, EGF-induced increased phosphorylation levels of p300 at Ser1834 was attenuated by 20 umol/L AG1478 (an EGFR tyrosine kinase inhibitor) and MK2206 (an Akt inhibitor) after 2 h coincubation in SNU-368 cells. Gefi, Gefitinib; MK, MK2206. **P < .01, ***P < .001, one-way ANOVA, n = 5 per group. Knockdown of p300 with two specific shRNAs could reverse EGF-induced HMGA2 mRNA (D) and protein (E) expression in SNU-368 cells, ***P < .001, one-way ANOVA, n = 6 per group. Expression of a phosphorylation-mimic p300 S1834D mutant could induce HMGA2 mRNA (F) and protein (G) in SNU-368 cells. ***P < .001, one-way ANOVA, n = 6 per group. H, ChIP analysis shows the amounts of p300 recruited to the HMGA2 promoter regions in SNU-368 cells treated with or without 100 ng/mL EGF for 12 h. *P < .05, **P < .01, two-tailed unpaired t test, n = 5 per group